Partners: Bnai Zion Medical Center, Haifa, Israel; Saarland University Hospital, Homburg, Germany; UMC Utrecht, Netherlands; Rabin Medical Center (Hasharon & Beilinson Medical Centers), Petah Tikva, Israel; Hillel Yafe, Hadera, Israel

DECODE’s objectives are:
1.     To deploy BV®/Key® at hospitals in Europe that are managing COVID-19 patients.
2.     To collect real world evidence to support the performance of BV in identifying early viral infection and predicting/monitoring disease severity of COVID-19 disease.
3.     To mature the BV / Key system based on lessons learned during deployment

Partners: Erasmus MC, Rotterdam, University Medical Center, Utrecht, Hadassah University Hospital, IBEXPERTS, University of Gothenburg, Noray Bioinformatics, and MeMed

At the heart of the Tailored-Treatment project is a prospective international clinical study designed to recruit and monitor 1200 hospitalized patients with respiratory tract and/or bloodstream infections. Cutting edge high-throughput techniques are used to measure the transcriptomic, proteomic and genomic fingerprint of these patients as well as their microbiome. The expected result is a unique multifaceted dataset that will be used to identify novel host-pathogen interactions and discover new biological markers of infection.

Partners: Rambam Health Care Campus, Carmel Medical Center and Rabin Medical Center (Beilinson Hospital)

The three-year award was granted through Horizon 2020’s Small and Medium-sized Enterprise (SME) instrument, which targets high potential SMEs with groundbreaking products that have the potential to profoundly impact the EU economy and global healthcare. MeMed’s proposal received top place out of 90 competitive applicants. Funds are being used to accelerate development of MeMed Key and validate MeMed BV on adults patients.

Partners: University of Perugia, University Hospital Mannheim, Tecan, Quantify Research, and MeMed

AutoPilot-Dx is an international consortium funded by the EU and led by MeMed with members from leading medical centers and industry that are coordinating the deployment of MeMed BV™ ELISA format in Europe to reduce antibiotic misuse in hospitals. Funds are being used to further solidify clinical utility and cost-effectiveness of MeMed BV™ ELISA format, with the goal of monitoring the management of 1,200 children with respiratory tract infections or fever without source. The two-year award was granted through the prestigious Horizon 2020 Fast Track to Innovation Pilot, which recognizes outstanding business innovators